US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Aardvark Therapeutics / Equity Capital Markets

<ul>
<li>We believe exercising caution based upon the small market cap of the company and the existing backers is the prudent play at this time.</li>
<li>Aardvark Therapeutics develops novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.</li>
<li>Their lead product candidate is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen and have initiated a Phase 3 trial for hyperphagia associated with PWS.</li>
</ul>


We believe exercising caution based upon the small market cap of the company and the existing backers is the prudent play at this time.
Aardvark Therapeutics develops novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Their lead product candidate is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen and have initiated a Phase 3 trial for hyperphagia associated with PWS.


Aardvark Therapeutics (AARD): Caution Needed Ahead of Small-Cap Obesity Biotech IPO

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>This is a special one-time report on Cue Health, a company once lauded for its promise in the diagnostics sector.</li><li>Amidst diminishing fortunes, the company is under the scrutiny of significant shareholder, Tarsadia Investments.</li><li>This report aims to dissect the various valuation scenarios underpinning Cue Health, providing a lucid understanding of its investment potential amidst the unfolding drama.</li></ul>

This is a special one-time report on Cue Health, a company once lauded for its promise in the diagnostics sector.Amidst diminishing fortunes, the company is under the scrutiny of significant shareholder, Tarsadia Investments.This report aims to dissect the various valuation scenarios underpinning Cue Health, providing a lucid understanding of its investment potential amidst the unfolding drama.

Cue Health Up For Sale: Tarsadia Pushes for Desperate Sale Amid Stock Plummet!

United States

Cue Health Inc. operates as a healthcare technology company. The Company develops and manufactures medical diagnostic products which are used in clinical and at-home settings. Cue Health serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cue Health (HLTH US)

Aardvark Therapeutics (AARD): Caution Needed Ahead of Small-Cap Obesity Biotech IPO

Exercising caution with Aardvark Therapeutics due to small market cap and existing backers; developing novel therapeutics for metabolic diseases...

IPO Boutique

Cue Health Up For Sale: Tarsadia Pushes for Desperate Sale Amid Stock Plummet!

This is a special one-time report on Cue Health, a company once lauded for its promise in the diagnostics sector. Amidst diminishing fortunes, the...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Aardvark Therapeutics (AARD): Caution Needed Ahead of Small-Cap Obesity Biotech IPO

​Exercising caution with Aardvark Therapeutics due to small market cap and existing backers; developing novel therapeutics for metabolic diseases...

IPO Boutique

Cue Health Up For Sale: Tarsadia Pushes for Desperate Sale Amid Stock Plummet!

This is a special one-time report on Cue Health, a company once lauded for its promise in the diagnostics sector. Amidst diminishing fortunes, the...

Baptista Research

Exercising caution with Aardvark Therapeutics due to small market cap and existing backers; developing novel therapeutics for metabolic diseases...